Whitehawk Therapeutics Inc (WHWK) Revenue History
Annual and quarterly revenue from 2019 to present
WHWK Revenue Over Time (2019–2025)
WHWK Revenue Growth History
4 of 6 years with positive growth- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- +1846.6%
- FY2021 revenue growth
- -92.3%
- FY2022 revenue growth
- +1258.6%
- FY2023 revenue growth
- +60.1%
- FY2024 revenue growth
- +6.7%
- FY2025 revenue growth
- -72.5%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $0 | -100.0% |
| Q3 2025 | $0 | -100.0% |
| Q2 2025 | $0 | -100.0% |
| Q1 2025 | $7.1M | +33.5% |
| Q4 2024 | $7.2M | +14.4% |
| Q3 2024 | $7.2M | +21.0% |
| Q2 2024 | $6.2M | -0.4% |
| Q1 2024 | $5.4M | -8.8% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
WHWK's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
WHWK Revenue Analysis (2019–2025)
Current Revenue & Growth
As of June 13, 2026, Whitehawk Therapeutics Inc (WHWK) generated trailing twelve-month (TTM) revenue of $7.1 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q4 2025) recorded $0 in revenue
Historical Growth Trajectory
WHWK's 5-year compound annual growth rate (CAGR) stands at -13.3%, indicating revenue contraction over this period. The 3-year CAGR of -22.3% is below the 5-year average, signalling a growth deceleration in recent years. Whitehawk Therapeutics Inc's highest annual revenue of $26.0 million was recorded in 2024.
Revenue by Segment
WHWK's revenue is primarily driven by Product (100%). With over half of revenue concentrated in Product, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including ACAD (+9.9% YoY), AXSM (+63.9% YoY), and INVA (+13.6% YoY) — WHWK has underperformed the peer group in revenue growth. Compare WHWK vs ACAD →
WHWK Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 WHWKCurrent | $7M | -100.0% | -13.3% | -1601.1% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 AXSM | $638M | +63.9% | - | -26.5% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 NRXP | $1M | - | - | -1324.4% |
WHWK Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7.1M | -72.5% | $6.4M | 89.4% | $-114,400,000 | -1601.1% |
| 2024 | $26.0M | +6.7% | $-28,071,000 | -108.0% | $-67,458,000 | -259.6% |
| 2023 | $24.4M | +60.1% | $-27,384,000 | -112.4% | $-71,933,000 | -295.4% |
| 2022 | $15.2M | +1258.6% | $-18,781,000 | -123.4% | $-62,681,000 | -411.9% |
| 2021 | $1.1M | -92.3% | $-18,550,000 | -1656.3% | $-111,217,000 | -9930.1% |
| 2020 | $14.6M | +1846.6% | $-428,000 | -2.9% | $-2,549,000 | -17.5% |
| 2019 | $749K | - | $-10,315,467 | -1377.2% | $-12,169,845 | -1624.8% |
What if you invested $1,000 in WHWK back in 2019?
Total return with dividends reinvested · 7+ years of data
Calculate ReturnsHow much would $100/month in WHWK be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs WHWK Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationWHWK vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowWHWK — Frequently Asked Questions
Quick answers to the most common questions about buying WHWK stock.
Is WHWK's revenue growth accelerating or slowing?
WHWK revenue is declining -100.0% year-over-year. TTM revenue fell to $7M, contrasting with the 5-year CAGR of -13.3%. The reversal reflects either macro headwinds or company-specific challenges.
What is WHWK's revenue history from 2019 to 2026?
Whitehawk Therapeutics Inc (WHWK) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $7M, growing at -100.0% YoY. The 5-year CAGR is -13.3%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is WHWK's long-term revenue growth rate (CAGR)?
Whitehawk Therapeutics Inc's 5-year revenue CAGR of -13.3% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -100.0% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for WHWK.
Why does WHWK's quarterly revenue fluctuate?
WHWK quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Whitehawk Therapeutics Inc's revenue data from 2019 to 2026 shows full historical quarterly detail on this page.
How is WHWK's revenue distributed by segment?
WHWK reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does WHWK's revenue compare to industry peers?
Whitehawk Therapeutics Inc (WHWK) with TTM revenue of $7M and -100.0% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.